Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

DRUG11 trials

Sponsors

Hoffmann-La Roche, Genentech, Inc.

Conditions

Advanced/Metastatic Head and Neck, Oesophageal and Cervical CancersCarcinoma, Non-Small-Cell LungCarcinoma, Non-Squamous Non-Small Cell LungMultiple MyelomaNon-Small Cell Lung CancerNon-Small-Cell LungRenal Cell CarcinomaSmall Cell Lung Carcinoma

Phase 1

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

CompletedNCT02431208

Hoffmann-La RocheMultiple Myeloma

Start: 2015-07-22End: 2021-03-19Updated: 2021-04-02

Phase 2

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

CompletedNCT01984242

Hoffmann-La RocheRenal Cell Carcinoma

Start: 2014-01-08End: 2019-01-08Updated: 2019-12-23

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

CompletedNCT02927301

Genentech, Inc.Non-Small Cell Lung Cancer

Start: 2017-04-20End: 2023-09-05Updated: 2024-09-19

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

TerminatedNCT03386721

Hoffmann-La RocheAdvanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers

Start: 2018-02-19End: 2021-12-30Updated: 2023-02-21

Phase 3

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT02366143

Hoffmann-La RocheCarcinoma, Non-Small-Cell Lung

Start: 2015-03-31End: 2020-12-07Updated: 2021-09-23

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT02367781

Hoffmann-La RocheCarcinoma, Non-Squamous Non-Small Cell Lung

Start: 2015-04-16End: 2021-01-18Updated: 2021-08-09

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

CompletedNCT02420821

Hoffmann-La RocheRenal Cell Carcinoma

Start: 2015-05-20End: 2021-12-13Updated: 2023-01-30

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

CompletedNCT02763579

Hoffmann-La RocheSmall Cell Lung Carcinoma

Start: 2016-06-07End: 2022-07-07Updated: 2023-07-28

A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy

CompletedNCT02813785

Hoffmann-La RocheCarcinoma, Non-Small-Cell Lung

Start: 2016-07-01End: 2022-12-27Updated: 2023-01-10

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

CompletedNCT03191786

Hoffmann-La RocheNon-Small Cell Lung Cancer

Start: 2017-09-11End: 2023-10-25Updated: 2024-10-23

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

CompletedNCT03456063

Hoffmann-La RocheNon-Small-Cell Lung

Start: 2018-04-24End: 2025-12-31Updated: 2026-01-22

Related Papers

Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters

Journal of Clinical Investigation2026-05-15

First-line atezolizumab monotherapy vs. single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation.

2025-12-17

Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.

2025-07-22

Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial

Nature Medicine2025-05-1615 citations

Discovery of mutations predictive of survival benefit from immunotherapy in first-line NSCLC: A retrospective machine learning study of IMpower150 liquid biopsy data.

2025-03-043 citations

Model-Based Meta Analysis for the IPSOS Trial in Platinum Ineligible NSCLC Patients

2025-02-18

R-index: a standardized representativeness metric for benchmarking diversity, equity, and inclusion in biopharmaceutical clinical trial development.

2025-01-311 citations

Association between incidence of hypomagnesemia and better prognosis of NSCLC: A case on the immortal time bias

The Innovation Medicine2025-01-011 citations

Atezolizumab monotherapy as first-line treatment for non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a cost-effectiveness analysis in the USA

BMJ Open2024-11-01

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.

2024-10-113 citations

Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy.

2024-08-1011 citations

BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).

Journal of Clinical Oncology2024-06-0121 citations

J-TAIL-2: A prospective, observational study of atezolizumab (atezo) combined with carboplatin and etoposide (CE) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) in Japan.

Journal of Clinical Oncology2024-06-01

Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer

Clinical Cancer Research2024-05-069 citations

IMpower210: A phase III study of second-line atezolizumab <i>vs.</i> docetaxel in East Asian patients with non-small cell lung cancer.

2024-04-015 citations

Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer

JCO Precision Oncology2024-03-0112 citations

Potential synergistic effects of cranial radiotherapy and atezolizumab in non-small cell lung cancer: an analysis of individual patient data from seven prospective trials.

2024-01-293 citations

Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab

Oncology and Therapy2024-01-274 citations

Neoadjuvant nivolumab plus chemotherapy in resectable non‐small‐cell lung cancer in Japanese patients from <scp>CheckMate</scp> 816

Cancer Science2023-12-1418 citations

Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.

2023-12-0717 citations

75 more papers not shown